School Choice Safari at ZooTampa to Help Families Navigate Educational Options

500 attendees expected for unique fair combining education exploration with family fun Hillsborough families seeking the best educational options for their children can do so in a one-of-a-kind setting at the School Choice Safari, hosted by GuidEd Florida. This unique event combines education exploration with family-friendly fun, creating an engaging experience for parents and students. […]

EliTe Solar Ranks #9 on Wood Mackenzie’s “Global Solar PV Module Manufacturers Ranking for H1 2024”

EliTe Solar, a global leader in integrated solar manufacturing, is proud to announce its ranking as #9 on Wood Mackenzie's prestigious”Global Solar PV Module Manufacturers Ranking for H1 2024.” This recognition underscores EliTe Solar's unwavering commitment to innovation, quality, and sustainability in the renewable energy industry. As a BloombergNEF Tier 1 company since 2012, EliTe

Civista Bancshares, Inc. Declares First Quarter Common Dividend

Civista Bancshares, Inc. (NASDAQ:CIVB) (“Civista”) announced today that the Board of Directors has approved a quarterly dividend of 17 cents per common share, an increase of 1 cent per common share from the prior quarter, to shareholders of record February 4, 2025, payable February 18, 2025. https://mma.prnewswire.com/media/241852/civista_bancshares_logo.jpg This dividend represents a payout of approximately $2.7

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

— Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion — Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1 — Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2 — Abbott projects full-year 2025 organic

Grounded Lithium Announces Completion of 2024 Field Program on the Kindersley Lithium Project and Provides PFS Progress Update

(TSXV: GRD) (OTCQB: GRDAF)- Grounded Lithium Corp. (“GLC” or the “Company”) announces completion of the 2024 field program and provides an update on the ongoing Pre-Feasibility Study (“PFS”) for the Kindersley Lithium Project (“KLP”). The Company, together with its strategic partner Denison Mines Corp. (“Denison”), completed a field drill program at the KLP's original 4-15-33-23W3

Today is Bell Let’s Talk Day! Everyone is invited to join the conversation and take action to support featured youth mental health organizations with national text-to-donate campaign

— Bell Let's Talk invites everyone to join Canada's 15th national day for mental health and take action to address the growing youth mental health crisis — Canadians can donate $5 by texting “YOUTH” to 45678 with Bell matching up to a total of $1 million; 100% of the proceeds going to six youth mental

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

(NASDAQ:OKYO), LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that

WOO X launches fee switch campaign, sharing trading volume with $WOO on-chain stakers for higher real yields

KINGSTOWN, St. Vincent and the Grenadines, Jan. 22, 2025 (GLOBE NEWSWIRE) — WOO X, a leading global centralized crypto trading platform known for its innovative trading solutions, has launched an exclusive reward event, with 0.1 bps of all spot and perpetual trading volumes allocated directly to WOO stakers from January 23 to February 6. “This

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

(NasdaqGM:CHRS), – Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor activity was observed across both viral and non-viral etiologies – – Data support continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC – – Randomized

Scroll to Top